Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
Joseph L. Witztum(University of California, San Diego), Éric Bruckert(Inserm), Karren Williams(Akebia Therapeutics (United States)), Steven D. Freedman(Hadassah Medical Center), Richard S. Geary(Ionis Pharmaceuticals (United States)), Fernando Civeira(Hospital Universitario Miguel Servet), Steven G. Hughes(Ionis Pharmaceuticals (United States)), Marcello Arca(Sapienza University of Rome), Dirk Blom(University of Cape Town), Veronica Alexander(Ionis Pharmaceuticals (United States)), Andrés Digenio(Akebia Therapeutics (United States)), Erik S.G. Stroes(Amsterdam UMC Location University of Amsterdam), Linda Hemphill(Massachusetts General Hospital), Daniel Gaudet(Brigham and Women's Hospital), Sotirios Tsimikas(University of California San Diego), Jean Bergeron(Centre hospitalier universitaire de Québec), Handrean Soran(Manchester University NHS Foundation Trust), Qingqing Yang, Louis O’Dea(Akebia Therapeutics (United States))
Cited by 663
Related Papers
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
|European Heart Journal|2013|2.7k
Role of oxidized low density lipoprotein in atherogenesis.
|Journal of Clinical Investigation|1991|2.7k
A comprehensive classification system for lipids
|Journal of Lipid Research|2005|1.8k
The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
|Nature Genetics|2000|1.8k